Abstract:The tumor microenvironment (TME) is crucial in cancer development and therapeutic response. Immunotherapy is increasingly recognized as a critical component of cancer treatment. While immunotherapies have shown efficacy in various cancers, including breast cancer, patient responses vary widely. Some patients receive significant benefits, while others experience minimal or no improvement. This disparity underscores the complexity and diversity of the immune system. In this study, we investigated the immune landscape and cell–cell communication within the TME of breast cancer through integrated analysis of bulk and single-cell RNA sequencing data. We established profiles of tumor immune infiltration that span across a broad spectrum of adaptive and innate immune cells. Our clustering analysis of immune infiltration identified three distinct patient groups: high T cell abundance, moderate infiltration, and low infiltration. Patients with low immune infiltration exhibited the poorest survival rates, while those in the moderate infiltration group showed better outcomes than those with high T cell abundance. Moreover, the high cell abundance group was associated with a greater tumor burden and higher rates of TP53 mutations, whereas the moderate infiltration group was characterized by a lower tumor burden and elevated PIK3CA mutations. Analysis of an independent single-cell RNA-seq breast cancer dataset confirmed the presence of similar infiltration patterns. Further investigation into ligand–receptor interactions within the TME unveiled significant variations in cell–cell communication patterns among these groups. Notably, we found that the signaling pathways SPP1 and EGF were exclusively active in the low immune infiltration group, suggesting their involvement in immune suppression. This work comprehensively characterizes the composition and dynamic interplay in the breast cancer TME. Our findings reveal associations between the extent of immune infiltration and clinical outcomes, providing valuable prognostic information for patient stratification. The unique mutations and signaling pathways associated with different patient groups offer insights into the mechanisms underlying diverse tumor immune infiltration and the formation of an immunosuppressive tumor microenvironment.

Tumor-infiltrating B cells: Their dual mechanistic roles in the tumor microenvironment

Implications for Cancer Immunology and Therapy

Immune Cells Within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy

Immune cells in the B-cell lymphoma microenvironment: From basic research to clinical applications

Single-Cell Informatics for Tumor Microenvironment and Immunotherapy

Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Biophysical and biochemical aspects of immune cell–tumor microenvironment interactions

Immunocytes interact directly with cancer cells in the tumor microenvironment: one coin with two sides and future perspectives

B cells present a double-sided effect in digestive system tumors: a review for tumor microenvironment

Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies

Tumor microenvironment as a complex milieu driving cancer progression: a mini review

The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy

Characterizing the Tumor Microenvironment and Its Prognostic Impact in Breast Cancer

New horizons in tumor microenvironment biology: challenges and opportunities

Innate Immune Cells in Tumour Microenvironment: A New Frontier in Cancer Immunotherapy

The Prognostic and Biology of Tumour-Infiltrating Lymphocytes in the Immunotherapy of Cancer

Yin-yang Effect of Tumor Infiltrating B Cells in Breast Cancer: from Mechanism to Immunotherapy.

Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells

Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies